TY - JOUR
T1 - Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines
AU - Correa, M. Elvira P.
AU - Cheng, Karis Kin Fong
AU - Chiang, Karen
AU - Kandwal, Abhishek
AU - Loprinzi, Charles L.
AU - Mori, Takehiko
AU - Potting, Carin
AU - Rouleau, Tanya
AU - Toro, Juan J.
AU - Ranna, Vinisha
AU - Vaddi, Anusha
AU - Peterson, Douglas E.
AU - Bossi, Paolo
AU - Lalla, Rajesh V.
AU - Elad, Sharon
N1 - Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Purpose: To update the 2013 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) clinical practice guidelines on oral cryotherapy for the management of oral mucositis (OM) caused by cancer therapies. Methods: A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The evidence for each intervention for specific cancer treatment modalities was assigned a level of evidence (LoE). The findings were added to the database used to develop the 2013 MASCC/ISOO clinical practice guidelines. Based on the LoE, the guidelines were set as: recommendation, suggestion, or no guideline possible. Results: A total of 114 papers were identified: 44 from PubMed and 70 from Web of Science. After abstract triage and merging with the 2013 database, 36 papers were reviewed. The LoE for prevention of OM with oral cryotherapy in patients undergoing autologous hematopoietic stem cell transplant using high-dose melphalan conditioning protocols was upgraded, and the guideline changed to recommendation. Additionally, the recommendation for prevention of OM with oral cryotherapy in patients receiving bolus 5-fluorouracil for the treatment of solid tumors was confirmed. No guidelines were possible for other clinical settings. Conclusions: The evidence supports recommendations for the use of oral cryotherapy for the prevention of OM for either (i) patients undergoing autologous hematopoietic stem cell transplant with high-dose melphalan conditioning protocols or (ii) patients receiving bolus 5-fluorouracil chemotherapy.
AB - Purpose: To update the 2013 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) clinical practice guidelines on oral cryotherapy for the management of oral mucositis (OM) caused by cancer therapies. Methods: A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The evidence for each intervention for specific cancer treatment modalities was assigned a level of evidence (LoE). The findings were added to the database used to develop the 2013 MASCC/ISOO clinical practice guidelines. Based on the LoE, the guidelines were set as: recommendation, suggestion, or no guideline possible. Results: A total of 114 papers were identified: 44 from PubMed and 70 from Web of Science. After abstract triage and merging with the 2013 database, 36 papers were reviewed. The LoE for prevention of OM with oral cryotherapy in patients undergoing autologous hematopoietic stem cell transplant using high-dose melphalan conditioning protocols was upgraded, and the guideline changed to recommendation. Additionally, the recommendation for prevention of OM with oral cryotherapy in patients receiving bolus 5-fluorouracil for the treatment of solid tumors was confirmed. No guidelines were possible for other clinical settings. Conclusions: The evidence supports recommendations for the use of oral cryotherapy for the prevention of OM for either (i) patients undergoing autologous hematopoietic stem cell transplant with high-dose melphalan conditioning protocols or (ii) patients receiving bolus 5-fluorouracil chemotherapy.
KW - Cancer
KW - Cryotherapy
KW - Guidelines
KW - Oral mucositis
UR - http://www.scopus.com/inward/record.url?scp=85076524237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076524237&partnerID=8YFLogxK
U2 - 10.1007/s00520-019-05217-x
DO - 10.1007/s00520-019-05217-x
M3 - Article
C2 - 31836937
AN - SCOPUS:85076524237
SN - 0941-4355
VL - 28
SP - 2449
EP - 2456
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 5
ER -